首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >The LeucoPatch® system in the management of hard-to-heal diabetic foot ulcers: study protocol for a randomised controlled trial
【2h】

The LeucoPatch® system in the management of hard-to-heal diabetic foot ulcers: study protocol for a randomised controlled trial

机译:LeucoPatch®系统在糖尿病足难治性溃疡的治疗中:一项随机对照试验的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundDiabetic foot ulcers are a common and severe complication of diabetes mellitus. Standard treatment includes debridement, offloading, management of infection and revascularisation where appropriate, although healing times may be long. The LeucoPatch® device is used to generate an autologous platelet-rich fibrin and leucocyte wound dressing produced from the patient’s own venous blood by centrifugation, but without the addition of any reagents. The final product comprises a thin, circular patch composed predominantly of fibrin together with living platelets and leucocytes. Promising results have been obtained in non-controlled studies this system, but this now needs to be tested in a randomised controlled trial (RCT). If confirmed, the LeucoPatch® may become an important new tool in the armamentarium in the management of diabetic foot ulcers which are hard-to-heal.
机译:背景技术糖尿病足溃疡是糖尿病的常见且严重的并发症。标准治疗包括清创,减负,感染管理和适当的血运重建,尽管治愈时间可能很长。 LeucoPatch®设备用于通过离心从患者自身的静脉血中产生自体富血小板血纤维蛋白和白细胞伤口敷料,但无需添加任何试剂。最终产品包括主要由血纤蛋白,活血小板和白细胞组成的薄而圆形的贴剂。在该系统的非对照研究中获得了可喜的结果,但现在需要在随机对照试验(RCT)中进行测试。如果得到证实,LeucoPatch®可能会成为难以治愈的糖尿病足溃疡的治疗中重要的新工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号